Financial Reports Latest Updates Industry Maps Economic Calendar

Kiniksa Pharmaceuticals International, plc (KNSA) Annual Reports

Q: Where can I read Kiniksa Pharmaceuticals International, plc (KNSA) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Kiniksa Pharmaceuticals International, plc is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1730430 →

Website：Official site ↗

Financial Highlights

FY2026 Q1 (quarterly, ended 2026-03-31)
	Current	Prior year	YoY
Revenue	$214.3M	$137.8M	+55.5%
Operating income	$29.3M	$13.3M	+120.5%
Net income	$22.6M	$8.5M	+164.6%
EPS (diluted)	$0.27	$0.11	+145.5%

Company guidance
	Period	Range
Revenue	—	$980M – $995M

Figures are the company’s own outlook as stated in its earnings release, not analyst estimates.

Source: SEC EDGAR (XBRL company facts); guidance from Form 8-K Exhibit 99.1

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 214 mn Net income 22.6 mn

Show table：Income statement

Item	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1
Revenue	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.70	12.1	18.8	32.2	27.0	99.1	61.9	48.4	71.5	67.0	83.4	79.9	109	112	123	138	157	181	202	214
Operating income	-11.4	-16.3	-32.7	-16.3	-21.5	-26.2	-44.1	-67.7	-39.3	-30.4	-32.6	-29.4	-31.9	-43.2	-52.9	-49.3	-40.5	-30.7	-36.1	-23.3	-19.4	46.4	6.05	-11.2	-3.15	-10.9	0.08	-16.5	-0.12	-9.66	-19.3	13.3	20.2	24.0	19.8	29.3
Net income	-11.2	-16.0	-32.7	-16.0	-20.3	-24.4	-42.6	-65.8	-37.2	-27.1	-31.8	-26.4	-37.5	-43.8	-53.7	-49.5	-41.6	-30.5	-36.3	-25.2	-20.0	224	4.46	-12.3	15.0	-13.8	25.2	-17.7	-3.91	-12.7	-8.89	8.54	17.8	18.4	14.2	22.6

Balance sheet

Quarterly · In mn (USD)

Total assets 825 mn Total liabilities 220 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1
Current assets	—	—	47.1	—	364	342	314	335	296	268	242	213	264	378	333	276	245	218	196	199	180	242	243	232	246	256	276	271	301	311	332	356	420	476	527	594
Total assets	—	—	47.5	—	365	347	322	346	308	282	255	226	271	384	349	311	279	253	233	231	211	460	460	443	484	483	526	520	542	555	581	599	661	712	764	825
Current liabilities	—	—	17.4	—	23.1	28.0	42.5	36.9	30.2	27.6	27.8	19.3	20.6	24.9	31.9	35.5	38.8	34.4	44.8	50.4	43.5	56.5	47.1	36.6	47.5	53.5	63.7	64.2	84.3	96.0	101	97.3	118	124	139	157
Total liabilities	—	—	17.4	—	23.3	28.2	42.7	39.6	32.9	29.9	29.1	20.3	21.0	25.9	37.5	40.5	43.4	38.8	47.8	64.7	57.1	75.9	63.5	52.8	72.7	77.9	87.5	87.8	107	118	142	142	166	177	196	220
Equity	—	—	-89.7	-105	342	319	279	307	275	252	225	206	250	359	312	271	236	214	185	166	153	384	396	390	412	405	439	432	435	437	438	457	495	535	568	606

Cash flow

Quarterly · In mn (USD)

Operating 50.2 mn Investing -31.9 mn Financing 6.07 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1
Operating	-15.9	-10.9	-23.4	-15.0	-17.9	-20.5	-27.6	-63.3	-41.7	-29.3	-24.2	-31.8	-29.2	-34.3	-41.2	-40.1	-38.8	-28.5	-18.9	-36.9	-7.82	62.0	-11.6	-4.27	-3.74	17.0	4.33	3.99	5.17	-2.24	18.8	22.3	28.1	33.7	53.9	50.2
Investing	-0.04	-0.03	0	-0.07	-73.9	-195	29.7	-9.28	41.4	15.2	1.92	88.8	-31.2	-150	68.6	44.8	86.0	47.9	-50.0	-22.7	38.3	19.0	-42.7	-37.9	35.5	-12.3	-14.9	25.5	-46.8	-6.35	65.3	-51.5	-3.88	-62.8	-70.8	-31.9
Financing	39.9	0	0	191	156	-0.76	0.29	83.2	0.49	0.05	0.37	2.41	77.6	146	0.71	1.11	0.89	2.68	1.21	0.42	0.54	0.36	1.19	0.09	0.16	0.55	0.7	3.61	-0.18	6.69	2.14	2.77	10.7	11.9	7.66	6.07
Cash at period end	80.0	69.0	45.6	221	286	69.7	72.0	82.6	82.8	68.8	46.9	106	123	85.9	114	120	168	190	122	63.3	94.3	176	123	80.6	113	118	108	141	99.3	97.4	184	157	192	175	166	190

Profitability

Quarterly · %

Operating margin 13.7% Net margin 10.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-526.4%	-253.6%	-192.8%	-72.4%	-71.8%	46.8%	9.8%	-23.2%	-4.4%	-16.3%	0.1%	-20.7%	-0.1%	-8.6%	-15.8%	9.6%	12.9%	13.3%	9.8%	13.7%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-539.5%	-252.5%	-193.8%	-78.3%	-74.1%	226.1%	7.2%	-25.4%	20.9%	-20.7%	30.3%	-22.2%	-3.6%	-11.3%	-7.3%	6.2%	11.4%	10.2%	7.0%	10.5%

Returns & leverage

Quarterly · %

ROE 13.7% ROA 10.3% Debt ratio 26.6%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1
ROE	—	—	—	—	-24.9%	-29.3%	-108.9%	-152.0%	-55.1%	-60.5%	-64.2%	-47.8%	-46.7%	-45.7%	-60.1%	-77.4%	-77.6%	-61.2%	-63.5%	-61.2%	-57.6%	47.7%	63.1%	70.6%	81.8%	-1.7%	3.4%	2.1%	-2.4%	-2.1%	-9.8%	-3.8%	1.0%	7.4%	11.7%	13.7%
ROA	—	—	—	—	-23.3%	-26.9%	-55.9%	-44.2%	-50.5%	-54.9%	-56.2%	-42.8%	-42.4%	-41.9%	-53.4%	-68.7%	-68.5%	-55.0%	-54.2%	-49.3%	-45.8%	40.0%	53.0%	58.3%	66.6%	-1.4%	2.9%	1.8%	-2.0%	-1.8%	-7.8%	-3.0%	0.8%	5.7%	8.8%	10.3%
Debt ratio	—	—	36.7%	—	6.4%	8.1%	13.3%	11.4%	10.7%	10.6%	11.4%	9.0%	7.8%	6.7%	10.7%	13.0%	15.6%	15.3%	20.5%	28.0%	27.1%	16.5%	13.8%	11.9%	15.0%	16.1%	16.6%	16.9%	19.8%	21.3%	24.5%	23.7%	25.1%	24.8%	25.7%	26.6%

EPS

Quarterly · US$

EPS US$0.27

Show table：EPS

Item	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1
EPS（US$）	—	—	—	—	—	—	—	—	—	—	-2.99	—	—	—	-2.61	-0.72	-0.61	-0.44	-0.52	-0.36	-0.29	3.18	0.05	-0.18	0.21	-0.20	0.36	-0.25	-0.06	-0.18	-0.12	0.11	0.23	0.23	0.18	0.27

Revenue & profit

Year-to-date · In mn (USD)

Revenue 214 mn Net income 22.6 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 825 mn Total liabilities 220 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating 50.2 mn Investing -31.9 mn Financing 6.07 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin 13.7% Net margin 10.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE 13.7% ROA 10.3% Debt ratio 26.6%

EPS

Year-to-date · US$

EPS US$0.27

Revenue & profit

Annual · In mn (USD)

Revenue 678 mn Net income 59.0 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	—	220	270	423	678
Operating income	-108	-170	-157	-157	9.77	-25.2	-45.6	77.2
Net income	-103	-162	-161	-158	183	14.1	-43.2	59.0

Balance sheet

Annual · In mn (USD)

Total assets 764 mn Total liabilities 196 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	314	242	333	196	243	276	332	527
Total assets	322	255	349	233	460	526	581	764
Current liabilities	42.5	27.8	31.9	44.8	47.1	63.7	101	139
Total liabilities	42.7	29.1	37.5	47.8	63.5	87.5	142	196
Equity	279	225	312	185	396	439	438	568

Cash flow

Annual · In mn (USD)

Operating 138 mn Investing -189 mn Financing 33.0 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-81.0	-158	-137	-126	5.81	13.3	25.7	138
Investing	-239	49.2	-23.4	129	-8.08	-29.6	37.7	-189
Financing	347	84.1	227	5.89	2.52	1.50	12.3	33.0
Cash at period end	72.0	46.9	114	122	123	108	184	166

Profitability

Annual · %

Operating margin 11.4% Net margin 8.7%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	—	4.4%	-9.3%	-10.8%	11.4%
Net margin	—	—	—	—	83.3%	5.2%	-10.2%	8.7%

Returns & leverage

Annual · %

ROE 11.7% ROA 8.8% Debt ratio 25.7%

Show table：Returns & leverage

Item	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-37.0%	-64.2%	-60.1%	-63.5%	63.1%	3.4%	-9.8%	11.7%
ROA	-32.1%	-56.2%	-53.4%	-54.2%	53.0%	2.9%	-7.8%	8.8%
Debt ratio	13.3%	11.4%	10.7%	20.5%	13.8%	16.6%	24.5%	25.7%

EPS

Annual · US$

EPS US$0.75

Show table：EPS

Item	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	-2.29	2.58	0.19	-0.61	0.75

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Kiniksa Pharmaceuticals International, plc (KNSA) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.